RSS Feeds
Use of Angiotensin-Converting Enzyme Inhibitors in Heart Failure and Renal Insufficiency
- Michael G. Shlipak, MD, MPH
- From Veterans Affairs Medical Center and University of California, San Francisco, San Francisco, CA 94121.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
I appreciate Dr. Ahmed's comments, and I agree that ACE inhibitors are likely to be beneficial in patients with systolic heart failure and renal insufficiency. The observational studies that demonstrate ACE inhibitor effectiveness in this setting are reassuring (1-3). However, subgroup analyses from randomized clinical trials of ACE inhibitors would add valuable and more definitive evidence to support the use of these agents in these patients.
Michael G. Shlipak, MD, MPH
Veterans Affairs Medical Center and University of California, San Francisco; San Francisco, CA 94121
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
